Stemline Therapeutics Announces Pricing of $76,250,000 Public Offering of Common Stock

NEXT STORY
Fennec Provides Business Update and Announces Second Quarter 2019 Financial Results
PREV STORY
Stedical Scientific Announces Completion of Acquisition of PermeaDerm, Inc.
Subscribe to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

CRISPR Therapeutics and MaSTherCell SA sign service agreement for the development and manufacturing of allogeneic cell therapies

BASEL, Switzerland and CAMBRIDGE, Mass. and GOSSELIES, Belgium, June 06, 2017 (GLOBE NEWSWIRE) -- ...

author_avatar
NASDAQ Market News

VBI Vaccines Hepatitis B Data Selected as Presidential Poster of Distinction at The Liver Meeting(R) 2017

CAMBRIDGE, MASSACHUSETTS--(Marketwired - Oct. 17, 2017) - VBI Vaccines Inc. (NASDAQ:VBIV)(TSX:VBV) (VBI) today announced ...

author_avatar
NASDAQ Market News

WATS3D Markedly Improves Detection of Esophageal Dysplasia and Barrett’s Esophagus in 12,899 Patient Study in the “Real World” Practice setting of 58 Community-Based Gastroenterologists

- New Study with Largest Data Set to Date Demonstrates that Adjunctive Use of ...

author_avatar
NASDAQ Market News